Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic Chronicle

The Psychedelic Chronicle provides the latest psychedelic news, research findings, informational guides & more from the world of psychedelics.

Our mission is to provide accurate, up-to-date information on psychedelics in a way that is clear, concise and easy to understand. We aim to be the go-to resource for anyone interested in learning about these powerful substances.

Mindset-Pharma-CEO-James-Lanthier-Exclusive-Interview-with-Psychedelic-Chronicle Psychedeic-Chronicle-Logo-White
Psychedelic CEO Interviews

Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis,

August 31, 2022
Cybin-Announces-Dosing-of-First-Patients-in-Phase-1-2a-Clinical-Trial-of-CYB003-Psilocybin-Analog-for-Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Cybin Announces Dosing of First Patients in Phase 1/2a Clinical Trial of CYB003 Psilocybin Analog for Depression

Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase

August 30, 2022
Revitalist-and-Awakn-Life-Sciences-Announce-Licensing-Partnership-for-Ketamine-Assisted-Therapy-for-Alcohol-Use-Disorder Psychedeic-Chronicle-Logo-White
Psychedelic News

Revitalist and Awakn Life Sciences Announce Licensing Partnership for Ketamine-Assisted Therapy for Alcohol Use Disorder

One of the largest publicly listed ketamine focused clinic operations operating in the United States, Revitalist Lifestyle and Wellness Ltd. (CSE: CALM)

August 15, 2022
Small-Pharma-Receive-UK-Regulatory-Approval-to-Begin-DMT-Assisted-Psychotherapy-and-SSRI-Drug-Interaction-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Small Pharma Receive UK Regulatory Approval to Begin DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare

August 15, 2022
Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia Psychedeic-Chronicle-Logo-White
Psychedelic News

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan

August 15, 2022
Field-Trip-Health-Wellness-Announce-19-Million-Financing-To-Trade-on-TSXV-Under-Ticker-FTHW Psychedeic-Chronicle-Logo-White
Psychedelic News

Field Trip Health & Wellness Announce $19.9 Million Financing, Will Trade on TSXV Under Ticker FTHW

Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares

August 15, 2022
Silo-Pharma-Announce-Topically-Administered-Ketamine-Delivers-Positive-Results-in-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Announce Topically Administered Ketamine Delivers Positive Results in Study

Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a

August 2, 2022
Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials

World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has

August 1, 2022
Filament Health Join TheraPsil in Worlds Largest Medical Psilocybin Access and Data Project Psychedeic-Chronicle-Logo-White
Psychedelic News

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the

July 28, 2022
Wellbeing KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex Psychedeic-Chronicle-Logo-White
Psychedelic News

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into

July 22, 2022

Recent Posts

  • Choose Ketamine Complete Capital Raise to Expand Technology Platform
  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Recent Comments

No comments to show.

Popular

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS